This study will be the first randomized placebo-controlled trial to evaluate the effect of inhibition of IL-1 using anakinra in the management of fever during neutropenia and mucositis, specifically in patients with multiple myeloma, treated with high-dose melphalan and HSCT. Here, IL1A is linked to plasma cell myeloma.